The Benefit of a Glucose-Sparing PD Therapy on Glycemic Control Measured by Serum Fructosamine in Diabetic Patients in a Randomized, Controlled Trial (IMPENDIA)

Nephron
Philip K T LiJoanne M Bargman

Abstract

Poor glycemic control can lead to increased morbidity and mortality in peritoneal dialysis (PD) patients. Serum fructosamine may be a more reliable marker of glycemic control than HbA1c in dialysis patients. We evaluated the effects of a glucose-sparing PD regimen on serum fructosamine. In the multicenter, controlled IMPENDIA trial, eligible diabetic PD patients were randomized (1:1) to a 24-hour combination of a glucose sparing regimen (n = 89) or a glucose-based therapy (n = 91). Serum fructosamine and HbA1c were measured at baseline, 3 months and 6 months; fructosamine measurements were corrected for serum albumin (AlbF). Serum fructosamine decreased from 297 to 253 µmol/l in the glucose-sparing group (95% confidence interval [CI] for the difference, -26 to -68, p < 0.001), and increased from 311 to 314 µmol/l in the glucose-only group (95% CI for the difference, -23 to +19, p = 0.87). The mean difference in change of fructosamine levels between groups at 6 months was 64 µmol/l (95% CI 29-99, p < 0.001). HbA1c decreased versus baseline in both groups (treatment difference 0.3%, p = 0.07). The correlation between AlbF and baseline fasting serum glucose was stronger than that seen between HbA1c and baseline fasting serum gluco...Continue Reading

Citations

Aug 5, 2015·Journal of Clinical Medicine·Nicanor Vega-DiazJosé Carlos Rodriguez-Perez
Feb 6, 2017·Seminars in Nephrology·Cheuk Chun Szeto, David W Johnson
Feb 6, 2017·Seminars in Nephrology·Philip Kam-Tao Li, Vickie Wai-Ki Kwong
Apr 15, 2017·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Melissa NataatmadjaUNKNOWN balANZ Trial Investigators
Aug 9, 2018·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Melissa S NataatmadjaUNKNOWN balANZ Trial Investigators
May 28, 2016·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Matthew B Rivara, Rajnish Mehrotra
Oct 27, 2018·The Cochrane Database of Systematic Reviews·Htay HtayYeoungjee Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.